“Epigenetic” modification as therapy for acute myeloid leukemia

E-ISSN： 1097-0142|124|2|242-244

ISSN： 0008-543x

Source： CANCER, Vol.124, Iss.2, 2018-01, pp. : 242-244

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy in acute myeloid leukemia

CANCER, Vol. 121, Iss. 16, 2015-08 ,pp. : 2689-2704

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 24, Iss. 4, 2001-09 ,pp. : 356-360

Karger

Access to resources Recommend Favorite

Therapy-Related Acute Myeloid Leukemia in Crohn’s Disease

Acta Haematologica, Vol. 129, Iss. 1, 2012-09 ,pp. : 20-22

Karger

Access to resources Recommend Favorite

Implications of FLT3 Mutations in the Therapy of Acute Myeloid Leukemia

Reviews on Recent Clinical Trials, Vol. 2, Iss. 2, 2007-05 ,pp. : 135-141

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 639-646

John Wiley & Sons Inc

Access to resources Recommend Favorite